Wells Fargo raised the firm’s price target on Boston Scientific (BSX) to $125 from $124 and keeps an Overweight rating on the shares. The firm reported Q3 revenue/EPS ahead of Street on strong PFA and Watchman strength. Q4 organic revenue and EPS guidance were ahead of Wells’ estimates. The firm believes that 10% organic growth in 2026 is a reasonable starting point. CHAMPION-AF data in early 2026 is next catalyst, Wells adds.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific’s Strong Performance and Promising Outlook Justifies Buy Rating
- Boston Scientific Reports Strong Q3 2025 Results
- Boston Scientific price target raised to $124 from $120 at Goldman Sachs
- Boston Scientific’s Strong Q3 Performance and WATCHMAN Growth Justify Buy Rating
- Boston Scientific’s Strong Financial Performance and Positive Outlook Earns Buy Rating